Company Analysis
Sign in

BGM Group Ltd. (BGM)

Nasdaq: BGM · Pharmaceutical Preparations · Chengdu, CN · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.3
◀ Past 4.6● Present 4.6▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$37.9M+51.1%
Net income-$19.9M-1282.1%
Earnings per share$-0.18+10.0%
Operating cash flow-$2.4M-535.9%
Cash$9.8M+0.0%
Debtn/a
Shareholders’ equity$392M+788.8%
Shares, diluted113.3M+1467.3%
Return on equity-5.1%
The recordfrom its filings
Filings in 202620
Newest filingSep 24 · 6-K
Annual reportJul 21, 2026
Quarterly reportn/a
Next report due20-F by Jan 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BGM · research, not advice